REPL

Replimune Group

• Seeking Alpha·10/13 21:55

  Replimune Group: A Hold Until TUDRIQEV's Commercial Potential Becomes Clear

• TipRanks·10/10 19:50

  Short Report: MiniMed short interest strikes another record high

• Simply Wall St·10/10 18:25

  Replimune Group (REPL) Could Be 44% Below Fair Value As TUDRIQEV Launch Begins

• Simply Wall St·10/08 11:41

  Tudriqev Launch Could Matter For Replimune Stock (REPL)

• Simply Wall St·10/02 20:18

  Is Replimune Group (REPL) Undervalued On Its TUDRIQEV Revenue Story?

• TipRanks·10/01 20:11

  Replimune announces Tudriqev now available in U.S. for advanced melanoma

• Benzinga·10/01 20:02

  Replimune Group Announces Commercial Availability Of TUDRIQEV In U.S. To Treat Unresectable Advanced Cutaneous Melanoma

• Simply Wall St·09/29 14:23

  How More Share Capacity Will Impact Replimune Group (REPL) Investors

• Simply Wall St·09/24 05:25

  Replimune Group (REPL) Could Be 46% Undervalued Following FDA Lawsuit Questions

• Seeking Alpha·09/23 15:03

  Compass Therapeutics downgraded at Wedbush as FDA seeks additional trial for lead asset

• Simply Wall St·09/22 12:24

  How More Authorized Shares Will Impact Replimune Group (REPL) Stock Investors

• TipRanks·09/16 20:34

  Replimune shareholders approve stock expansion and governance items

• Benzinga·09/16 20:11

  Replimune Says Stockholders Approved Amendment To Increase Authorized Common Shares From 150M To 300M, Effective September 15

• The Wall Street Journal·09/16 09:30

  Trump Administration Shift Puts This Corner of Biotech Back in Favor - Heard on the Street

• Simply Wall St·09/16 02:25

  Is Replimune Group (REPL) Fully Valued Following Its RP1 Class Action News?